AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Study identifier:D7405C00001

ClinicalTrials.gov identifier:NCT06137118

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Medical condition

B-cell acute lymphoblastic leukemia (B-ALL)

Phase

Phase 1/2

Healthy volunteers

No

Study drug

AZD0486

Sex

All

Estimated Enrollment

120

Study type

Interventional

Age

12 Years - 80 Years

Date

Study Start Date: 29 Dec 2023
Estimated Primary Completion Date: 29 Jan 2026
Estimated Study Completion Date: 04 Feb 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria